Advances in sampling and screening for chlamydia

Future Microbiology

Volumn 8, Issue 3, 2013, Pages 367-386

  Hocking, Jane S ^a   Guy, Rebecca ^b   Walker, Jennifer ^c   Tabrizi, Sepehr N ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chlamydia trachomatis; NAAT; organism load; point of care; screening; self collected specimen; serovar; sexually transmitted infection; testing

Indexed keywords

RNA 23S;

BACTERIAL TRANSMISSION; CHLAMYDIA; CHLAMYDIA RAPID TEST; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; DRUG TREATMENT FAILURE; ECTOPIC PREGNANCY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MORBIDITY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; ORCHITIS; PELVIC INFLAMMATORY DISEASE; POINT OF CARE TESTING; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE;

BACTERIOLOGICAL TECHNIQUES; CHLAMYDIA; CHLAMYDIA INFECTIONS; HUMANS; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; SELF ADMINISTRATION; SEXUALLY TRANSMITTED DISEASES; SPECIMEN HANDLING;

EID: 84874734018     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.3     Document Type: Review

References (221)

1. Schachter J, Stephens RS. Biology of Chlamydia trachomatis. In: Sexually Transmitted Disease (4th Edition). Holmes KK, Sparling PF, Stamm WE et al. (Eds). McGraw-Hill, NY, USA, 555-574 (2008).
2. WHO. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections. WHO, Switzerland (2012).
3. CDC. CDC Grand Rounds: chlamydia prevention: challenges and strategies for reducing disease burden and sequelae. MMWR Morb. Mortal. Wkly Rep. 60(12), 370-373 (2011).
4. Vickers DM, Osgood ND. Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling. BMC Infect. Dis. 10, 70 (2010).
5. O'Rouke K, Fairley C, Samaranayake A, Collingnon P, Hocking J. Trends in chlamydia positivity over time among women in Melbourne Australia, 2003-2007. Sex. Transm. Dis. 36(12), 763-767 (2009).
6. Vodstrcil LA, Fairley CK, Fehler G et al. Trends in chlamydia and gonorrhea positivity among heterosexual men and men who have sex with men attending a large urban sexual health service in Australia, 2002-2009. BMC Infect. Dis. 11, 158 (2011).
7. Goetz H, Lindbaèck J, Ripa T, Malin Arneborn, Ramstedt K, Ekdahl K. Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods? Scand. J. Infect. Dis. 34(1), 28-34 (2002).
8. Eggleston E, Rogers SM, Turner CF et al. Chlamydia trachomatis infection among 15-35-year-olds in Baltimore, MD. Sex. Transm. Dis. 38(8), 743-749 (2011).
9. Fenton K, Copas A, Mitchell K et al. The acceptability of urinary LCR testing for Chlamydia trachomatis among participants in a probability sample survey of sexual attitudes and lifestyles. Sex. Transm. Infect. 77(3), 194-198 (2001).
10. Hocking J, Willis J, Tabrizi S, Hellard M, Garland S, Fairley CK. A chlamydia prevalence survey of young women living in Melbourne, Victoria. Sex. Health 3, 235-240 (2006).
11. Goulet V, de Barbeyrac B, Raherison S et al. Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France. Sex. Transm. Infect. 86(4), 263-270 (2010).
12. Klovstad H, Grjibovski A, Aavitsland P. Population based study of genital Chlamydia trachomatis prevalence and associated factors in Norway: a cross sectional study. BMC Infect. Dis. 12, 150 (2012).
13. Datta SD, Torrone E, Kruszon-Moran D et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008. Sex. Transm. Dis. 39(2), 92-96 (2012).
14. Fine D, Thomas KK, Nakatsukasa-Ono W, Marrazzo J. Chlamydia positivity in women screened in family planning clinics: racial/ ethnic differences and trends in the northwest U.S., 1997-2006. Public Health Rep. 127(1), 38-51 (2012).
15. Rao GG, Bacon L, Evans J et al. Prevalence of Neisseria gonorrhoeae infection in young subjects attending community clinics in South London. Sex. Transm. Infect. 84(2), 117-121 (2008).
16. Low N, Sterne JAC, Barlow D. Inequalities in rates of gonorrhoea and chlamydia between black ethnic groups in south east London: cross sectional study. Sex. Transm. Infect. 77, 15-20 (2001).
17. Gotz HM, Veldhuijzen IK, Ossewaarde JM, de Zwart O, Richardus JH. Chlamydia trachomatis infections in multi-ethnic urban youth: a pilot combining STI health education and outreach testing in Rotterdam, Netherlands. Sex. Transm. Infect. 82(2), 148-152; discussion 152-143 (2006).
18. Lewis D, Newton D, Guy R et al. The prevalence of Chlamydia trachomatis infection in Australia: a systematic review and meta-analysis. BMC Infect. Dis. 12, 113 (2012).
19. Annan NT, Sullivan AK, Nori A et al. Rectal chlamydia - a reservoir of undiagnosed infection in men who have sex with men. Sex. Transm. Infect. 85(3), 176-179 (2009).
20. Centers for Disease Control and Prevention. Clinic-based testing for rectal and pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections by community-based organizations - five cities, United States, 2007. MMWR Morb. Mortal. Wkly Rep. 58(26), 716-719 (2009).
21. Kent CK, Chaw JK, Wong W et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin. Infect. Dis. 41(1), 67-74 (2005).
22. Peipert JF. Genital chlamydial infections. N. Engl. J. Med. 349(25), 2424-2430 (2003).
23. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J. Infect. Dis. 201(Suppl. 2), S134-S155 (2010).
24. van Valkengoed IGM, Morre SA, van den Brule AJC, Meijer CJLM, Bouter LM, Boeke AJP. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes - implications for cost-effectiveness analyses. Int. J. Epidemiol. 33, 416-425 (2004).
25. Oakeshott P, Kerry S, Aghaizu A et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 340, c1642 (2010).
26. Wiesenfeld HC, Hillier SL, Krohn MA et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet. Gynecol. 100(3), 456-463 (2002).
27. Walker J, Fairley C, Bradshaw C et al. Chlamydia trachomatis incidence and re-infection among young women - behavioural and microbiological characteristics. PLoS One 7(5), e37778 (2012).
28. LaMontagne D, Baster K, Emmett L et al. Incidence and reinfection rates of genital chlamydia infection among women aged 16 to 24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex. Transm. Infect. 83, 282-303 (2007).
29. Batteiger BE, Tu W, Ofner S et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J. Infect. Dis. 201(1), 42- 51 (2010).
30. Hosenfeld CB, Workowski KA, Berman S et al. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex. Transm. Dis. 36(8), 478-489 (2009).
31. Handsfield HH. Questionning azithromycin for chlamydial infection. Sex. Transm. Dis. 38(11), 1028-1029 (2011).
32. Horner P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex. Transm. Infect. 82, 340-343 (2006).
33. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex. Transm. Infect. 88(3), 154-156 (2012).
34. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol. 5(9), 1427-1442 (2010).
35. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J. Infect. Dis. 191(6), 917-923 (2005).
36. Golden MR, Whittington WL, Handsfield HH et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhoea or chlamydial infection. N. Engl. J. Med. 352, 676-685 (2005).
37. Schwebke J, Rompalo A, Taylor S et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens - a randomized clinical trial. Clin. Infect. Dis. 52(2), 163-170 (2011).
38. Tabrizi SN, Chen S, Borg AJ et al. Patient-administered tampon-collected genital cells in the assessment of Chlamydia trachomatis infection using polymerase chain reaction. Sex. Transm. Dis. 23(6), 494-497 (1996).
39. Goldenberg S, Shoveller J, Koehoorn M, Ostry A. Barriers to STI testing among youth in a Canadian oil and gas community. Health Place 14(4), 718-729 (2008).
40. Kimmitt PT, Tabrizi SN, Crosatti M et al. Pilot study of the utility and acceptability of tampon sampling for the diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis infections by duplex realtime polymerase chain reaction in United Kingdom sex workers. Int. J. STD AIDS 21(4), 279-282 (2010).
41. Bradshaw CS, Pierce LI, Tabrizi SN, Fairley CK, Garland SM. Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling. Sex. Transm. Infect. 81(1), 53-58 (2005).
42. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb. Mortal. Wkly Rep. 59(RR-12), 1-110 (2010).
43. European Centre for Disease Prevention and Control Guidance. Chlamydia Control in Europe. European Centre for Disease Prevention and Control, Sweden (2009).
44. Harris M, Bailey L, Bridges-Webb C, Ackermann E. Guidelines for Preventive Activities in General Practice (the Red Book) (8th Edition). Royal Australian College of General Practitioners, Australia (2012).
45. Low N, Cassell JA, Spencer B et al. Chlamydia control activities in Europe: cross-sectional survey. Eur. J. Pub. Health 22(4), 556-561 (2011).
46. Low N, Egger M. What should we do about screening for genital chlamydia? Int. J. Epidemiol. 31, 891-893 (2002).
47. Low N, Bender N, Nartey L, Shang A, Stephenson JM. Effectiveness of chlamydia screening: systematic review. Int. J. Epidemiol. 38, 435-448 (2009).
48. van den Broek IVF, van Bergen JEAM, Brouwers EEHG et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 345, e4316 (2012).
49. Jensen BL, Hoff G, Weismann K. A comparison of an enzyme immunoassay and cell culture for detection of Chlamydia trachomatis in genito-urinary specimens. Sex. Transm. Dis. 15(2), 123-126 (1988).
50. Fletcher RH, Fletcher SW. Clinical Epidemiology: The Essentials. Lippincott, Williams and Wilkins, PA, USA (2005).
51. Hadgu A, Sternberg M. Reproducibility and specificity concerns associated with nucleic acid amplification tests for detecting Chlamydia trachomatis. Eur. J. Clin. Microbiol. Infect. Dis. 28(1), 9-15 (2009).
52. Hadgu A. Issues in Chlamydia trachomatis testing by nucleic acid amplification test. J. Infect. Dis. 193(9), 1335-1336; author reply 1338-1339 (2006).
53. Hadgu A, Dendukuri N, Hilden J. Evaluation of nucleic acid amplification tests in the absence of a perfect gold-standard test: a review of the statistical and epidemiologic issues. Epidemiology 16(5), 604-612 (2005).
54. Schachter J, Stamm WE, Quinn TC. Discrepant analysis and screening for Chlamydia trachomatis. Lancet 351(9097), 217-218 (1998).
55. Hilden J. Discrepant analysis - or behaviour? Lancet 350(9082), 902 (1997).
56. Miller WC. Bias in discrepant analysis: when two wrongs don't make a right. J. Clin. Epidemiol. 51(3), 219-231 (1998).
57. Hadgu A, Dendukuri N, Wang L. Evaluation of screening tests for detecting Chlamydia trachomatis: bias associated with the patient-infected-status algorithm. Epidemiology 23(1), 72-82 (2012).
58. US FDA. Establishing the Performance Characteristics of In Vitro Diagnostic Devices for Chlamydia trachomatis and/or Neisseria gonorrhoea: Screening and Diagnostic Testing. US FDA, MD, USA (2011).
59. Van Der Pol B, Liesenfeld O, Williams JA et al. Performance of the cobas CT/NG test compared to the Aptima AC2 and Viper CTQ/ GCQ assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J. Clin. Microbiol. 50(7), 2244-2249 (2012).
60. Gronowski AM, Copper S, Baorto D, Murray PR. Reproducibility problems with the Abbott laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae. J. Clin. Microbiol. 38(6), 2416-2418 (2000).
61. Culler EE, Caliendo AM, Nolte FS. Reproducibility of positive test results in the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J. Clin. Microbiol. 41(8), 3911-3914 (2003).
62. Castriciano S, Luinstra K, Jang D et al. Accuracy of results obtained by performing a second ligase chain reaction assay and PCR analysis on urine samples with positive or near-cutoff results in the LCx test for Chlamydia trachomatis. J. Clin. Microbiol. 40(7), 2632-2634 (2002).
63. Boel CHE, van Herk CMC, Berretty PJM, Onland GHW, van den Brule AJC. Evaluation of conventional and real-time PCR assays using two targets for confirmation of results of the COBAS AMPLICOR Chlamydia trachomatis/ Neisseria gonorrhoeae test for detection of Neisseria gonorrhoeae in clinical samples. J. Clin. Microbiol. 43(5), 2231-2235 (2005).
64. Verkooyen RP, Noordhoek GT, Klapper PE et al. Reliability of nucleic acid amplification methods for detection of Chlamydia trachomatis in urine: results of the first international collaborative quality control study among 96 laboratories. J. Clin. Microbiol. 41(7), 3013-3016 (2003).
65. Schachter J, Chow JM, Howard H, Bolan G, Moncada J. Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. J. Clin. Microbiol. 44(7), 2512-2517 (2006).
66. Morre SA, Sillekens PT, Jacobs MV et al. Monitoring of Chlamydia trachomatis infections after antibiotic treatment using RNA detection by nucleic acid sequence based amplification. Mol. Pathol. 51(3), 149-154 (1998).
67. Lewis N, Dube G, Carter C et al. Chlamydia and gonorrhoea contamination of clinic surfaces. Sex. Transm. Infect. 88(6), 418-421 (2012).
68. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex. Health 8(1), 69-73 (2011).
69. Dukers-Muijrers NHTM, Morre SA, Speksnijder A, van der Sande MAB, Hoebe CJPA. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One, 7(3), e34108 (2012).
70. Ripa T, Nilsson P. A variant of Chlamydia trachomatis with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. Eurosurveillance 11(11), E061109.2. (2006).
71. Ripa T, Nilsson P. A Chlamydia trachomatis strain with a 377-bp deletion in the cryptic plasmid causing falsenegative nucleic acid amplification tests. Sex. Transm. Dis. 34, 255-256 (2007).
72. Soderblom T, Blaxhult A, Fredlund H, Herrmann B. Impact of a genetic variant of Chlamydia trachomatis on national detection rates in Sweden. Eurosurveillance 11(12), E061207.1. (2006).
73. Kangas I, Andersen B, Olsen F, Moller J, Ostergaard L. Psychosocial impact of Chlamydia trachomatis testing in general practice. Br. J. Gen. Pract. 56, 587-593 (2006).
74. France C, Thomas K, Slack R, James N. Psychosocial impacts of chlamydia testing are important. BMJ 322, 1245 (2001).
75. Duncan B, Hart G, Scoular A, Bigrigg A. Qualitative analysis of psychosocial impact of diagnosis of Chlamydia trachomatis: implication for screening. BMJ 322, 195-199 (2001).
76. Pavlin N, Gunn JM, Parker R, Fairley CK, Hocking J. Implementing chlamydia screening: what do women think? A systematic review of the literature. BMC Public Health 6, 221-231 (2006).
77. Pasternack R, Vuorinen P, Miettinen A. Evaluation of the Gen-Probe Chlamydia trachomatis transcription-mediated amplification assay with urine specimens from women. J. Clin. Microbiol. 35(3), 676-678 (1997).
78. Ostergaard L, Moller JK, Andersen B, Olesen F. Diagnosis of urogenital Chlamydia trachomatis infection in women based on mailed samples obtained at home: multipractice comparative study. BMJ 313(7066), 1186-1189 (1996).
79. Chernesky MA, Lee H, Schachter J et al. Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. J. Infect. Dis. 170(5), 1308-1311 (1994).
80. Chernesky MA, Jang D, Lee H et al. Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction. J. Clin. Microbiol. 32(11), 2682-2685 (1994).
81. Bianchi A, Scieux C, Brunat N et al. An evaluation of the polymerase chain reaction amplicor Chlamydia trachomatis in male urine and female urogenital specimens. Sex. Transm. Dis. 21(4), 196-200 (1994).
82. Williams J, van der Pol B, Rosenberger J, Ott M. Evaluation of the UriSwab sponge collection device for the detection of Chlamydia trachomatis in urine. Presented at: International Society of STD Research. London, UK, July 2009.
83. Garrow SC, Smith DW, Harnett GB. The diagnosis of chlamydia, gonorrhoea and trichomonas infections by self obtained low vaginal swabs, in remote northern Australian clinical practice. Sex. Transm. Infect. 78(4), 278-281 (2002).
84. Knox J, Tabrizi SN, Miller P et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex. Transm. Dis. 29(11), 647-654 (2002).
85. Schachter J, McCormack WM, Chernesky MA et al. Vaginal swabs are appropriate specimens for diagnosis of genital chlamydia tract infection with Chlamydia trachomatis. J. Clin. Microbiol. 41(8), 3784-3789 (2003).
86. Hsieh Y-H, Howell MR, Gaydos JC, McKee KT, Quinn TC, Gaydos CA. Preference among female army recruits for use of self-administered vaginal swabs or urine to screen for Chlamydia trachomatis genital infections. Sex. Transm. Dis. 30(10), 769-773 (2003).
87. Chernesky MA, Hook EW, 3rd, Martin DH et al. Women find it easy and prefer to collect their own vaginal swabs to diagnose Chlamydia trachomatis or Neisseria gonorrhoeae infections. Sex. Transm. Dis. 32(12), 729-733 (2005).
88. Schachter J, Chernesky MA, Willis DE et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex. Transm. Dis. 32(12), 725-728 (2005).
89. Chandeying V, Lamlertkittikul S, Skov S. A comparison of first-void urine, self-administered low vaginal swab, self-inserted tampon, and endocervical swab using PCR tests for the detection of infection with Chlamydia trachomatis. Sex. Health 1(1), 51-54 (2004).
90. Wiesenfeld HC, Lowry DL, Heine RP et al. Self-collection of vaginal swabs for the detection of chlamydia, gonorrhea, and trichomoniasis: opportunity to encourage sexually transmitted disease testing among adolescents. Sex. Transm. Dis. 28(6), 321-325 (2001).
91. Doshi JS, Power J, Allen E. Acceptability of chlamydia screening using self-taken vaginal swabs. Int. J. STD AIDS 19(8), 507-509 (2008).
92. Hoebe CJPA, Rademaker CW, Brouwers EEHG, ter Waarbeek HLG, van Bergen JEAM. Acceptability of self-taken vaginal swabs and first-catch urine samples for the diagnosis of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae with an amplified DNA assay in young women attending a public health sexually transmitted disease clinic. Sex. Transm. Dis. 33(8), 491-495 (2006).
93. Alary M, Poulin C, Bouchard C et al. Evaluation of a modified sanitary napkin as a sample self-collection device for the detection of genital chlamydial infection in women. J. Clin. Microbiol. 39(7), 2508-2512 (2001).
94. Tabrizi SN, Paterson B, Fairley CK, Bowden FJ, Garland SM. A self-administered technique for the detection of sexually transmitted diseases in remote communities. J. Infect. Dis. 176(1), 289-292 (1997).
95. Bowden FJ, Paterson BA, Tabrizi SN, Fairley CK, Garland SM. Using self-administered tampons to diagnose STDs. AIDS Patient Care STDs 12(1), 29-32 (1998).
96. Tabrizi SN, Paterson BA, Fairley CK, Bowden FJ, Garland SM. Comparison of tampon and urine as self-administered methods of specimen collection in the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women. Int. J. STD AIDS 9(6), 347-349 (1998).
97. Tabrizi SN, Fairley CK, Cehn S et al. Evaluation of patient-administered tampon specimens for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex. Transm. Dis. 27(3), 133-137 (2000).
98. Garland SM, Tabrizi SN. Diagnosis of sexually transmitted infections (STI) using self-collected non-invasive specimens. Sex. Health 1(2), 121-126 (2004).
99. Tabrizi S, Chen S, Fairley C et al. Tampon-collected genital cells in the detection of Chlamydia trachomatis by polymerase chain reaction. J. Infect. Dis. 168(3), 796-797 (1993).
100. Smith BL, Cummings MC, Benes S, McCormack WM. Evaluation of vaginal tampons for collection of specimens for detection of chlamydial infection. Sex. Transm. Dis. 23(2), 127-130 (1996).
101. Chai SJ, Aumakhan B, Barnes M et al. Internet-based screening for sexually transmitted infections to reach nonclinic populations in the community: risk factors for infection in men. Sex. Transm. Dis. 37(12), 756-763 (2010).
102. Alexander S, Ison C, Parry J et al. Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex. Transm. Infect. 84(6), 488-492 (2008).
103. Moncada J, Schachter J, Liska S, Shayevich C, Klausner JD. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of nucleic acid amplification tests. J. Clin. Microbiol. 47(6), 1657-1662 (2009).
104. van der Helm JJ, Hoebe CJPA, van Rooijen MS et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex. Transm. Dis. 36(8), 493-497 (2009).
105. Twin J, Moore EE, Garland SM et al. Chlamydia trachomatis genotypes among men who have sex with men in Australia. Sex. Transm. Dis. 38(4), 279-285 (2011).
106. Freeman A, Bernstein K, Kohn R, Philip S, Rauch L, Klausner J. Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. Sex. Transm. Dis. 38(11), 1036-1039 (2011).
107. Tabrizi S. Diagnosis of Chlamydia trachomatis using self collected non-invasive specimens - the Australian experience. Microbiol. Aust. 28(1) 10-12 (2007).
108. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann. Intern. Med. 142(11), 914-925 (2005).
109. Marrazzo JM, Scholes D. Acceptability of urine-based screening for Chlamydia trachomatis in asymptomatic young men: a systematic review. Sex. Transm. Dis. 35(11 Suppl.), S28-S33 (2008).
110. Serlin M, Shafer M-A, Tebb K et al. What sexually transmitted disease screening method does the adolescent prefer? Adolescents' attitudes toward first-void urine, self-collected vaginal swab, and pelvic examination. Arch. Pediatr. Adolesc. Med. 156(6), 588-591 (2002).
111. Morre SA, van Valkengoed IG, de Jong A et al. Mailed, home-obtained urine specimens: a reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. J. Clin. Microbiol. 37(4), 976-980 (1999).
112. van Dommelen L, Dukers-Muijrers N, van Tiel FH, Brouwers EEHG, Hoebe CJPA. Evaluation of one-sample testing of self-obtained vaginal swabs and first catch urine samples separately and in combination for the detection of Chlamydia trachomatis by two amplified DNA assays in women visiting a sexually transmitted disease clinic. Sex. Transm. Dis. 38(6), 533-535 (2011).
113. Skidmore S, Horner P, Herring A et al. Vulvovaginal-swab or first-catch urine specimen to detect Chlamydia trachomatis in women in a community setting? J. Clin. Microbiol. 44(12), 4389-4394 (2006).
114. Hook EW 3rd, Smith K, Mullen C et al. Diagnosis of genitourinary Chlamydia trachomatis infections by using the ligase chain reaction on patient-obtained vaginal swabs. J. Clin. Microbiol. 35(8), 2133-2135 (1997).
115. Geisler WM. Diagnosis and management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: summary of evidence reviewed for the 2010 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin. Infect. Dis. 53(Suppl. 3), S92-S98 (2011).
116. Gaydos CA, Farshy C, Barnes M et al. Can mailed swab samples be dry-shipped for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by nucleic acid amplification tests? Diagn. Microbiol. Infect. Dis. 73(1), 16-20 (2012).
117. Alexander S, Martin I, Ison C. Confirming the Chlamydia trachomatis status of referred rectal specimens. Sex. Transm. Infect. 83(4), 327-329 (2007).
118. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex. Transm. Dis. 35(7), 637-642 (2008).
119. Tipple C, Hill SC, Smith A. Is screening for pharyngeal Chlamydia trachomatis warranted in high-risk groups? Int. J. STD AIDS 21(11), 770-771 (2010).
120. Peters RPH, Nijsten N, Mutsaers J, Jansen CL, Morre SA, van Leeuwen AP. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex. Transm. Dis. 38(9), 783-787 (2011).
121. Royal Australasian College of Physicians. Sexually Transmitted Infection Testing Guidelines for Men Who Have Sex With Men 2010. Royal Australasian College of Physicians, New Zealand (2010).
122. Ostergaard L, Andersen B, Olesen F, Moller JK. Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study. BMJ 317(7150), 26-27 (1998).
123. Pannekoek Y, Westenberg SM, de Vries J et al. PCR assessment of Chlamydia trachomatis infection of semen specimens processed for artificial insemination. J. Clin. Microbiol. 38(10), 3763-3767 (2000).
124. Rodger A, Hocking J, Warren R, Snow J, Aboagye-Kwarteng T, Crofts N. Prevalence of genital Chlamydia trachomatis in male clients of female sex workers in Melbourne. Venereology 12(4), 129-132 (1999).
125. Tabrizi S, Skov S, Chandeying V, Norpech J, Garland S. Prevalence of sexually transmitted infections among clients of female commercial sex workers in Thailand. Sex. Transm. Dis. 27(6), 358-362 (2000).
126. Shafer M-A, Moncada J, Boyer CB, Betsinger K, Flinn SD, Schachter J. Comparing first-void urine specimens, self-collected vaginal swabs, and endocervical specimens to detect Chlamydia trachomatis and Neisseria gonorrhoeae by a nucleic acid amplification test. J. Clin. Microbiol. 41(9), 4395-4399 (2003).
127. Richardson E, Sellors JW, Mackinnon S et al. Prevalence of Chlamydia trachomatis infections and specimen collection preference among women, using self-collected vaginal swabs in community settings. Sex. Transm. Dis. 30(12), 880-885 (2003).
128. Tilson EC, Sanchez V, Ford CL et al. Barriers to asymptomatic screening and other STD services for adolescents and young adults: focus group discussions. BMC Public Health 4, 21 (2004).
129. Warr D, Hillier L. "That's the problem with living in a small town": privacy and sexual health issues for young rural people. Aust. J. Rural Health 5(3), 132-139 (1997).
130. Wang LY, Burstein GR, Cohen DA. An economic evaluation of a school-based sexually transmitted disease screening program. Sex. Transm. Dis. 29(12), 737-745 (2002).
131. Nsuami M, Cohen DA. Participation in a school-based sexually transmitted disease screening program. Sex. Transm. Dis. 27(8), 473-479 (2000).
132. Burstein GR, Waterfield G, Joffe A, Zenilman JM, Quinn TC, Gaydos CA. Screening for gonorrhea and chlamydia by DNA amplification in adolescents attending middle school health centers. Opportunity for early intervention. Sex. Transm. Dis. 25(8), 395-402 (1998).
133. Braun RA, Provost JM. Bridging the gap: using school-based health services to improve chlamydia screening among young women. Am. J. Public Health 100(9), 1624-1629 (2010).
134. Bowden FJ, O'Keefe EJ, Primrose R, Currie MJ. Sexually transmitted infections, blood-borne viruses and risk behaviour in an Australian senior high school population - the SHLiRP study. Sex. Health 2(4), 229- 236 (2005).
135. Debattista J, Martin P, Jamieson J et al. Detection of Chlamydia trachomatis in an Australian high school student population. Sex. Transm. Infect. 78(3), 194-197 (2002).
136. Barry PM, Scott KC, McCright J et al. Stay in school? Results of a sexually transmitted diseases screening program in San Francisco high schools-2007. Sex. Transm. Dis. 35(6), 550-552 (2008).
137. Kent CK, Branzuela A, Fischer L, Bascom T, Klausner JD. Chlamydia and gonorrhea screening in San Francisco high schools. Sex. Transm. Dis. 29(7), 373-375 (2002).
138. Asbel LE, Newbern EC, Salmon M, Spain CV, Goldberg M. School-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae among Philadelphia public high school students. Sex. Transm. Dis. 33(10), 614-620 (2006).
139. Cohen DA, Nsuami M, Etame RB et al. A school-based chlamydia control program using DNA amplification technology. Pediatrics 101(1), E1 (1998).
140. Joffe A, Rietmeijer CA, Chung S-E et al. Screening asymptomatic adolescent men for Chlamydia trachomatis in school-based health centers using urine-based nucleic acid amplification tests. Sex. Transm. Dis. 35(Suppl. 11), S19-s23 (2008).
141. Gaydos CA, Hsieh YH, Galbraith JS, Barnes M, Waterfield G, Stanton B. Focus-on-Teens, sexual risk-reduction intervention for high-school adolescents: impact on knowledge, change of risk-behaviours, and prevalence of sexually transmitted diseases. Int. J. STD AIDS 19(10), 704-710 (2008).
142. Gold J, Hocking J, Hellard M. The feasibility of recruiting young men in rural areas from community football clubs for STI screening. Aust. NZ J. Public Health 31(3), 243-246 (2007).
143. Kong FYS, Hocking JS, Link CK, Chen MY, Hellard ME. Sex and sport: chlamydia screening in rural sporting clubs. BMC Infect. Dis. 9, 73 (2009).
144. Debattista J, Clementson C, Mason D et al. Screening for Neisseria gonorrhoeae and Chlamydia trachomatis at entertainment venues among men who have sex with men. Sex. Transm. Dis. 29(4), 216-221 (2002).
145. Debattista J, Dwyer J, Orth D, Lister G, Patten J. Community screening for Neisseria gonorrhoeae and Chlamydia trachomatis among patrons of sex-on-premises venues: two years later. Venereology 13(3), 105-109 (2000).
146. Lister N, Smith A, Tabrizi S et al. Screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men at male-only saunas. Sex. Transm. Dis. 30(12), 886-889 (2003).
147. Lambert NL, Fisher M, Imrie J et al. Community based syphilis screening: feasibility, acceptability, and effectiveness in case finding. Sex. Transm. Infect. 81(3), 213-216 (2005).
148. Mayer KH, Ducharme R, Zaller ND et al. Unprotected sex, underestimated risk, undiagnosed HIV and sexually transmitted diseases among men who have sex with men accessing testing services in a New England bathhouse. J. Acquir. Immune Defic. Syndr. 59(2), 194-198 (2012).
149. Buhrer-Skinner M, Muller R, Menon A, Gordon R. Novel approach to an effective community-based chlamydia screening program within the routine operation of a primary healthcare service. Sex. Health 6(1), 51-56 (2009).
150. Martin L, Freedman E, Burton L et al. The C-project: use of self-collection kits to screen for Chlamydia trachomatis in young people in a community-based health promotion project. Sex. Health 6(2), 157-162 (2009).
151. Cwikel JG, Lazer T, Press F, Lazer S. Sexually transmissible infections among female sex workers: an international review with an emphasis on hard-to-access populations. Sex. Health 5(1), 9-16 (2008).
152. Morton AN, Wakefield T, Tabrizi SN, Garland SM, Fairley CK. An outreach programme for sexually transmitted infection screening in street sex workers using self-administered samples. Int. J. STD AIDS 10(11), 741-743 (1999).
153. Mak RP, Van Renterghem L, Traen A. Chlamydia trachomatis in female sex workers in Belgium: 1998-2003. Sex. Transm. Infect. 81(1), 89-90 (2005).
154. Macauley S, Creighton S. Testing commercial sex workers for chlamydia and gonorrhoea on outreach. Sex. Transm. Infect. 85(3), 231-232 (2009).
155. Van Leeuwen JM, Rietmeijer CA, LeRoux T, White R, Petersen J. Reaching homeless youths for Chlamydia trachomatis and Neisseria gonorrhoeae screening in Denver, Colorado. Sex. Transm. Infect. 78(5), 357-359 (2002).
156. Auerswald CL, Sugano E, Ellen JM, Klausner JD. Street-based STD testing and treatment of homeless youth are feasible, acceptable and effective. J. Adolesc. Health 38(3), 208-212 (2006).
157. Grimley DM, Annang L, Lewis I et al. Sexually transmitted infections among urban shelter clients. Sex. Transm. Dis. 33(11), 666-669 (2006).
158. Bradshaw CS, Pierce LI, Tabrizi SN, Fairley CK, Garland SM. Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling. Sex. Transm. Infect. 81(1), 53-58 (2005).
159. Peterman TA, Newman DR, Goldberg M et al. Screening male prisoners for Chlamydia trachomatis: impact on test positivity among women from their neighborhoods who were tested in family planning clinics. Sex. Transm. Dis. 36(7), 425-429 (2009).
160. Mertz KJ, Schwebke JR, Gaydos CA, Beidinger HA, Tulloch SD, Levine WC. Screening women in jails for chlamydial and gonococcal infection using urine tests: feasibility, acceptability, prevalence, and treatment rates. Sex. Transm. Dis. 29(5), 271-276 (2002).
161. Davies SC, Karagiannis T, Headon V, Wiig R, Duffy J. Prevalence of genital chlamydial infection among a community sample of young international backpackers in Sydney, Australia. Int. J. STD AIDS 22(3), 160-164 (2011).
162. Bloom MS, Hu Z, Gaydos JC, Brundage JF, Tobler SK. Incidence rates of pelvic inflammatory disease diagnoses among Army and Navy recruits potential impacts of chlamydia screening policies. Am. J. Prev. Med. 34(6), 471-477 (2008).
163. Greenland KE, Op de Coul ELM, van Bergen JEAM et al. Acceptability of the internet-based chlamydia screening implementation in The Netherlands and insights into nonresponse. Sex. Transm. Dis. 38(6), 467-474 (2011).
164. Gaydos CA, Dwyer K, Barnes M et al. Internet-based screening for Chlamydia trachomatis to reach non-clinic populations with mailed self-administered vaginal swabs. Sex. Transm. Dis. 33(7), 451-457 (2006).
165. Masek BJ, Arora N, Quinn N et al. Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an internet-based screening program. J. Clin. Microbiol. 47(6), 1663-1667 (2009).
166. Gaydos CA, Barnes M, Aumakhan B et al. Chlamydia trachomatis age-specific prevalence in women who used an internet-based self- screening program compared to women who were screened in family planning clinics. Sex. Transm. Dis. 38(2), 74-78 (2011).
167. Jenkins WD, Rabins C, Barnes M, Agreda P, Gaydos C. Use of the internet and self-collected samples as a sexually transmissible infection intervention in rural Illinois communities. Sex. Health 8(1), 79-85 (2011).
168. Novak D, Novak M. Use of the internet for home testing for Chlamydia trachomatis in Sweden: who are the users? Int. J. STD AIDS 23(2), 83-87 (2012).
169. Shih SL, Graseck AS, Secura GM, Peipert JF. Screening for sexually transmitted infections at home or in the clinic? Curr. Opin. Infect. Dis. 24(1), 78-84 (2011).
170. Baraitser P, Pearce V, Holmes J, Horne N, Boynton PM. Chlamydia testing in community pharmacies: evaluation of a feasibility pilot in south east London. Qual. Saf. Health Care 16(4), 303-307 (2007).
171. Brabin L, Thomas G, Hopkins M, O'Brien K, Roberts SA. Delivery of chlamydia screening to young women requesting emergency hormonal contraception at pharmacies in Manchester, UK: a prospective study. BMC Womens Health 9, 7 (2009).
172. Anderson C, Thornley T. A pharmacy-based private chlamydia screening programme: results from the first 2 years of screening and treatment. Int.J. Clin. Pharm. 33(1), 88-91 (2011).
173. Health Protection Agency. Annual Report of the National Chlamydia Screening Programme in England 2006/7. National Chlamydia Screening Programme, UK (2007).
174. Department of Health. Boots Selected to Provide Free Chlamydia Screening for 16-24 Year Olds Across the Capital. Department of Health, UK (2005).
175. Sexual Health Society of Victoria. National Management Guidelines for Sexually Transmissible Infections. Sexual Health Society of Victoria, Australia (2008).
176. Guy R, Hocking J, Low N et al. Interventions to increase rescreening for repeat chlamydial infection. Sex. Transm. Dis. 39(2), 136-146 (2012).
177. Mukenge-Tshibaka L, Alary M, Lowndes CM et al. Syndromic versus laboratory-based diagnosis of cervical infections among female sex workers in Benin: implications of nonattendance for return visits. Sex. Transm. Dis. 29(6), 324-330 (2002).
178. Vickerman P, Watts C, Alary M, Mabey D, Peeling RW. Sensitivity requirements for the point of care diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in women. Sex. Transm. Infect. 79(5), 363-367 (2003).
179. Guy R, Ward JS, Smith KS et al. The impact of sexually transmissible infection programs in remote Aboriginal communities in Australia: a systematic review. Sex. Health 9(3), 205-212 (2012).
180. Gift TL, Pate MS, Hook EW 3rd, Kassler WJ. The rapid test paradox: when fewer cases detected lead to more cases treated: a decision analysis of tests for Chlamydia trachomatis. Sex. Transm. Dis. 26(4), 232-240 (1999).
181. Hislop J, Quayyum Z, Flett G, Boachie C, Fraser C, Mowatt G. Systematic review of the clinical effectiveness and cost- effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. Health Technol. Assess. 14(29), 1-97, iii-iv (2010).
182. Huang W, Gaydos CA, Barnes MR, Jett- Goheen M, Blake DR. Comparative effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting. Sex. Transm. Infect. doi:10.1136/sextrans-2011-050355 (2012) (Epub ahead of print).
183. Bowden FJ. Reappraising the value of urine leukocyte esterase testing in the age of nucleic acid amplification. Sex. Transm. Dis. 25(6), 322-326 (1998).
184. van Dommelen L, van Tiel FH, Ouburg S et al. Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex. Transm. Infect. 86(5), 355-359 (2010).
185. Nadala E-C, Goh BT, Magbanua J-P et al. Performance evaluation of a new rapid urine test for chlamydia in men: prospective cohort study. BMJ 339, b2655 (2009).
186. GeneXpert Technology: a look to the future. Presented at: Association for Molecular Pathology Annual Meeting, Grapevine, TX, USA, 17-19 November 2011.
187. Goldenberg SD, Finn J, Sedudzi E, White JA, Tong CYW. Performance of the GeneXpert CT/NG assay compared to that of the Aptima AC2 Assay for detection of rectal Chlamydia trachomatis and Neisseria gonorrhoeae by use of residual aptima samples. J. Clin. Microbiol. 50(12), 3867-3869 (2012).
188. Peeling RW. Applying new technologies for diagnosing sexually transmitted infections in resource-poor settings. Sex. Transm. Infect. 87(Suppl. 2), ii28-ii30 (2011).
189. Piepenburg O, Williams CH, Stemple DL, Armes NA. DNA detection using recombination proteins. PLoS Biol. 4(7), e204 (2006).
190. Zhang Y, Agreda P, Kelley S, Gaydos C, Geddes CD. Development of a microwave-accelerated metal-enhanced fluorescence 40 second, <100 cfu/ml point of care assay for the detection of Chlamydia trachomatis. IEEE Trans. Biomed. Eng. 58(3), 781-784 (2011).
191. Christerson L, Ruettger A, Gravningen K, Ehricht R, Sachse K, Herrmann B. High-resolution genotyping of Chlamydia trachomatis by use of a novel multilocus typing DNA microarray. J. Clin. Microbiol. 49(8), 2838-2843 (2011).
192. Gravningen K, Christerson L, Furberg A-S et al. Multilocus sequence typing of genital Chlamydia trachomatis in Norway reveals multiple new sequence types and a large genetic diversity. PLoS One 7(3), e34452 (2012).
193. Stevens MP, Tabrizi SN, Muller R, Krause V, Garland SM. Characterization of Chlamydia trachomatis omp1 genotypes detected in eye swab samples from remote Australian communities. J. Clin. Microbiol. 42(6), 2501-2507 (2004).
194. Geisler WM, Black CM, Bandea CI, Morrison SG. Chlamydia trachomatis OmpA genotyping as a tool for studying the natural history of genital chlamydial infection. Sex. Transm. Infect. 84(7), 541-544; discussion 544-545 (2008).
195. Wylie JL, Cabral T, Jolly AM. Identification of networks of sexually transmitted infection: a molecular, geographic, and social network analysis. J. Infect. Dis. 191(6), 899-906 (2005).
196. Eckert LO, Suchland RJ, Hawes SE, Stamm WE. Quantitative Chlamydia trachomatis cultures: correlation of chlamydial inclusion-forming units with serovar, age, sex, and race. J. Infect. Dis. 182(2), 540-544 (2000).
197. Rogers SM, Miller WC, Turner CF et al. Concordance of Chlamydia trachomatis infections within sexual partnerships. Sex. Transm. Infect. 84(1), 23-28 (2007).
198. Geisler WM, Suchland RJ, Whittington WL, Stamm WE. Quantitative culture of Chlamydia trachomatis: relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease. J. Infect. Dis. 184(10), 1350-1354 (2001).
199. Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J. Infect. Dis. 201(Suppl. 2), S178-S189 (2010).
200. Gomes JP, Borrego MJ, Atik B et al. Correlating Chlamydia trachomatis infectious load with urogenital ecological success and disease pathogenesis. Microbes Infect. 8(1), 16-26 (2006).
201. Molano M, Meijer CJLM, Weiderpass E et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J. Infect. Dis. 191, 907-916 (2005).
202. Gray RT, Beagley KW, Timms P, Wilson DP. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J. Infect. Dis. 199(11), 1680-1688 (2009).
203. Jones RB, Vanderpol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J. Infect. Dis. 162(6), 1309-1315 (1990).
204. Lefevre JC, Lepargneur JP. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex. Transm. Dis. 25(7), 350-352 (1998).
205. Mourad A, Sweet RL, Sugg N, Schachter J. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob. Agents Chemother. 18(5), 696-698 (1980).
206. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 181(4), 1421-1427 (2000).
207. Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 56(5), 371-377 (2010).
208. Shkarupeta MM, Lazarev VN, Akopian TA, Afrikanova TS, Govorun VM. Analysis of antibiotic resistance markers in Chlamydia trachomatis clinical isolates obtained after ineffective antibiotic therapy. Bull. Exp. Biol. Med. 143(6), 713-717 (2007).
209. Zhu H, Wang HP, Jiang Y, Hou SP, Liu YJ, Liu QZ. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in Chlamydia trachomatis strains selected in vitro by macrolide passage. Andrologia 42(4), 274-280 (2010).
210. Misyurina OY, Chipitsyna EV, Finashutina YP et al. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob. Agents Chemother. 48(4), 1347-1349 (2004).
211. NHS. National Chlamydia Screening Programme. www.chlamydiascreening.nhs. uk
212. Australian Chlamydia Control Effectiveness Pilot. www.accept.org.au
213. I want the Kit. John Hopkin's University. www.iwantthekit.org
214. WHO. Mapping the landscape of diagnostics for sexually transmitted infections. www.who.int/tdr/publications/documents/ mapping-landscape-sti.pdf
215. Cepheid Xpert® CT/NG Product Information. www.cepheid.com/product- catalog/clinical-ivd-tests/xpert-ctng
216. Smittskyddsinstitutet (SMI). Chlamydia Infection. www. smittskyddsinstitutet.se/in-english/ statistics/chlamydia-infection
217. Statens Serum Institut. www.ssi.dk/data
218. CDC WONDER Online Database. www.wonder.cdc.gov/std-v2008.html
219. Public Health Agency of Canada. Reported cases and rates of chlamydia by province/ territory and sex, 1991 to 2009. www.phac-aspc.gc.ca/std-mts/sti-its- tab/ chlamydia-pts-eng.php
220. Australian Government. Department of Health and Ageing. National Notifiable Diseases Surveillance System. www.health.gov.au/cda/source/CDA-index. cfm
221. Health Protection Agency. Sexually Transmitted Infections Annual Data. www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/STIs/ STIsAnnualDataTables/#2.-STI-data-tables